VivoSeq
Ophthalmology

Retinal Vein Occlusion

42

Pipeline Programs↗

2

Active Trials↗

18

Companies Involved↗

Retinal Vein Occlusion is a moderately active landscape with 42 programs across 18 companies. The most active players are Fovea Pharmaceuticals SA, Aerie Pharmaceuticals, Chengdu Kanghong Biotech Co., Ltd.. 9 therapies are approved with 13 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

57/100

Pipeline Velocity

11/100

Mech. Concentration

31/100

Completion Rate

91/100

Attrition Rate

7/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

F

Fovea Pharmaceuticals SA

1 program

Phase 1A

Aerie Pharmaceuticals

2 programs

Phase 2C

Chengdu Kanghong Biotech Co., Ltd.

1 program

Phase 2S

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

1 program

Phase 2A

Annexin Pharmaceuticals AB

1 program

Phase 2O

Ohr Pharmaceutical Inc.

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

75%

Small molecule

43 of 57 classified programs — the dominant modality here.

25%ALL OTHERSMonoclonal antibody916%Protein / enzyme47%Peptide12%

Small molecule leads; the ring shows all 57 classified programs, each share of the total. Modality classified for 100% of 59 pipeline programs.

Analysis

Trial Status

122

clinical trials

Completed88 · 72%
Unknown status23 · 19%
Terminated8 · 7%
Recruiting2 · 2%
Withdrawn1 · 1%

Clinical Trials

Trial Activity

122 trials

Mecobalamin Combined With Anti-VEGF Intravitreal Injection for Retinal Vein Occlusion Treatment
Recruiting·FFirst Affiliated Hospital of Chongqing Medical University·Phase 4·NCT07133438·120 enrolled
Safety and Proof of Concept Study of ANXV (Annexin A5) in Patients With Diabetic Retinopathy or Retinal Vein Occlusion
Recruiting·AAnnexin Pharmaceuticals AB·Phase 2·NCT07259928·12 enrolled
Combined Triple Procedure in Retinal Vein Occlusion (RVO)
Completed·JJohann Wolfgang Goethe University Hospital·Phase 3·NCT00805064·40 enrolled
To Study the Effectiveness and Safety of Niacin and a Topical Steroid Eye Drop to Treat Retinal Vein Occlusions
Completed·PPalo Alto Medical Foundation·Phase 2/3·NCT00493064·63 enrolled
Conbercept Ophthalmic Injection for Patients With Macular Edema Caused by Branch Retinal Vein Occlusion
Completed·CChengdu Kanghong Biotech Co., Ltd.·Phase 3·NCT03108352·255 enrolled
An Extension Study to Evaluate Safety and Tolerability of Ranibizumab in Macular Edema Secondary to Retinal Vein Occlusion (Cohort 2)
Completed·Roche logoRoche·N/A·NCT01442064·608 enrolled
TLC399 (ProDex) in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)
Completed·TTaiwan Liposome Company·Phase 2·NCT03093701·31 enrolled
Safety and Effectiveness of Bevacizumab Intravitreal Injections in the Treatment of Macular Edema Secondary to Retinal Vein Occlusion
Completed·IInstituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA·Phase 3·NCT00970957·107 enrolled
Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With Central Retinal Vein Occlusion (CRVO)
Completed·Novartis logoNovartis·Phase 3·NCT01396083·243 enrolled
REtinal Vein OccLUsion Treatment With Scatter Laser Guided by UWFA in combiNAtion With Ranibizumab Study
Completed·RRetina Associates of Florida, P.A.·Phase 2·NCT01247220·12 enrolled
Hemodilution Versus Ranibizumab in Early-onset Central Retinal Vein Occlusion
Completed·—·Phase 4·NCT01448018·45 enrolled
601 Versus Ranibizumab in Patients With Central Retinal Vein Occlusion (CRVO)
Completed·SSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.·Phase 2·NCT04667910·60 enrolled
Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)
Completed·Regeneron logoRegeneron·Phase 3·NCT00943072·189 enrolled
Eylea and Lucentis for Macular Edema in Branch Retinal Vein Occlusion
Completed·SSt. Erik Eye Hospital·Phase 4·NCT03709745·110 enrolled
Retrospective Data Analysis of Patients Treated for Macular Edema Due to Central Retinal Vein Occlusion
Completed·Bayer logoBayer·N/A·NCT02645747·126 enrolled
Page 1 of 9

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)